BPS 2022 Proceedings

ACCESS REQUIRED TO VIEW PRESENTATION RECORDINGS

Videos of each presentation are available for purchase through a subscription. PURCHASE

Meienhofer Keynote Address

Stephen Kent

Professor
University of Chicago

Chemical Protein Synthesis - my Journey from SPPS to Chemical Ligation

Peptide Showcase

Brief 15 minute presentations from companies developing peptide therapeutics and related technologies. This rapid and compressed format is designed for quick introduction between symposium participants to new technologies, and companies. Each presentation is structured to highlight the value of the technology or therapeutic being offered and the business strategy.

Ved Srivastava

Vice President, chemistry
Aktis Oncology

Realizing the curative power of alpha radiopharmaceuticals for mainstream cancer care

Sally Wang Liang

SVP of BD
PepLib

Beyond Binders: High-Throughput Peptide Screening for Functionally Active Hits

John McGee

Vice President and Scientific Co-Founder
FOG Pharmaceuticals Inc

Platforms for the Rapid Discovery of Helical Peptide Therapeutics

Dominik Sarma

Managing Director
Belyntic GmbH

Faster time-to-market with Peptide Easy Clean (PEC)

Dani Stoltzfus

Senior Director R & D Chemistry
NeuBase Therapeutics

Developing PNAs into Biotherapeutics

Massina Abderrahmane

Data Scientist
Iktos Inc

Representing, predicting, and generating simple and complex peptides

Morten Lundh

Project Leader
Gubra

The streaMLine platform for accelerated clinical candidate identification

Lucas Siow

CEO and Co-Founder
ProteinQure Inc

Structure-driven exploration of non-canonical amino acid space for optimized peptide ligands

Patrick Salveson

VP Research and Discovery
Vilya

Computational macrocycle design with drug-like properties for targeted therapeutics

Spotlight on Discovery

Presentations of applied research from the academic labs.

Ashlee Rowe

Assistant Professor
University of Oklahoma

Structure and Mechanism of a Novel Scorpion Peptide that Inhibits Nav1.8, a Voltage-Gated Sodium Channel Regulator of . . .

Christina Schroeder

Senior Fellow
Genentech

Recifin A, a Novel and Selective Allosteric Inhibitor of Tyrosyl-DNA Phosphodiesterase I with a Unique Disulfide-bond . . .

Helena Safavi-Hemami

Associate Professor
University of Copenhagen, Denmark

Hormone-Like Peptides from Venomous Animals as Optimized Drug Leads for Disease

Peptides in the Clinic

Updates on clinical development of peptide therapeutics.

Bernhard Fischer

CEO
APEPTICO

Clinical development of the solnatide peptide for the treatment of ARDS and COVID-19 during the corona pandemics. . . .

Johannes Koebberling

Senior Science Fellow
Bayer AG

Discovery and Early Development of Adrenomedullin Pegol (BAY 1097761) for the Treatment of ARDS - First Disclosure

Thomas Kruse

Senior Principal Scientist
Novo Nordisk

Preclinical and Clinical Development of Long-acting Amylin Agonists

Dieter Willbold

Director
Forschungszentrum Jülich

The All-D-Peptide PRI-002: Preclinical PoC and Clinical Phase Ib Data from Alzheimer’s Disease Patients

Geoff Harris

Founder Ocelot Bio
Ocelot Bio

Designing a Mixed Agonist-Antagonist Peptide: A Case Study of OCE-205 in Advanced Liver Disease

David Huang

CMO
Peptilogics

Engineered Peptide PLG0206 Overcomes Activity, Safety, and Pharmacokinetic Limitations of a Challenging Drug Class

Drug Delivery

Novel approaches to peptide drug delivery including devices, molecular engineering, conjugation, and formulation technologies

Kevin McDonnell

VP Chemistry
Bicycle Therapeutics

Bicycles® are versatile vehicles for precision guided drug delivery

John Lewis

Professor
University of Alberta

Fusogenix Proteolipid Vehicles (PLVs) utilize fusion-associated transmembrane proteins to deliver DNA or RNA by direct . . .

Manuel Sanchez-Felix

Senior Fellow
Novartis

Patient-centric design for systemic peptide delivery: Trends in routes of administration and advancement in drug . . .

Ratmir Derda

Chief Operating Officer
48Hour Discovery

Novel, Peptide-Based Radiopharmaceuticals for the Treatment of Various Solid Tumors

Patrick Dougherty

Senior Scientist
Entrada Therapeutics

Development of Endosomal Escape Vehicles to Enhance the Intracellular Delivery of Oligonucleotides

Chemistry of Complex Peptides

Hiroaki Suga

Professor
The University of Tokyo

Display and RaPID Selection of Pseudo-Natural Peptides and Products

Les Miranda

Executive Director, R&D & CMC Operations
Amgen

GIPR antagonist antibodies conjugated to GLP-1 peptide are multispecific molecules that decrease weight in obese mice . . .

Michael Stowell

Professor
University of Colorado - Boulder

Structural Complexities of Insulin Receptor Signaling

Michal Avital-Shmilovici

Senior Scientist and Research Lead
SRI International

Mega-Throughput Screening of Large OBOC Non-Natural Peptide Libraries Using Fiber Optic Array Scanning Technology

Patrick Knerr

Senior Director & Site Head
Novo Nordisk Research Center Indianapolis

Discovery and Optimization of Long-Acting, Unimolecular Peptide Triple Agonists of the GLP-1, GIP, and Glucagon . . .

Workshops and Panels

Pharma Circle Panel

Jakob Fuhrmann

Principal Scientist
Genentech

BIO

Greg Adams

Associate Director Discovery Chemistry • Drug Design
Former Merck & Co. / Currently at Exscientia

BIO

Sandeep Somani

Principal Scientist
Janssen Research and Development

BIO

Moderator - Chengzao Sun

Sr. Principal Scientist
Janssen, Inc.

BIO

Start-Up Workshop

Maria Soloveychik

CEO
SyntheX

BIO

Sally Wang Liang

SVP of BD
PepLib

BIO

Cristina Rondinone

Founder/CEO
Pep2Tango Therapeutics Inc

BIO

Rami Hannoush

General Partner and Chief Scientific Officer
Mubadala Capital

BIO

Hiroaki Suga

Professor
The University of Tokyo

BIO

Dave Garman

Chief Technology Officer
NoNO Inc.

BIO

Moderator - Ewa Lis

CEO
Koliber Biosciences Inc.

BIO

CEO Roundtable Discussion

Thomas Meier

CEO
Bachem Holding AG

BIO

Raymond De Vré

CEO
PolyPeptide Group

BIO

Mike Collins

President & CEO
CEM Corporation

BIO

Moderator - Trishul Shah

Director of Business Development
Polypeptide Group

BIO

September 15-18, 2025

LIVE, In Person at the St. Julien Hotel in Boulder, Colorado

The only conference focused solely on the pharmaceutical development of peptide therapeutics.